Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 20/20 | 0.54 |
| ▸ | CA1 | P00915 | 20/20 | 0.54 |
| ▸ | CA2 | P00918 | 20/20 | 0.54 |
| ▸ | CA7 | P43166 | 20/20 | 0.54 |
| ▸ | CA9 | Q16790 | 20/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 17/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19930456 | 0.86 | ALDH1A1 (0.44) | — | |
| SCHEMBL19930462 | 0.86 | ALDH1A1 (0.64) | — | |
| SCHEMBL19930448 | 0.85 | SLC6A7 (0.55) | — | |
| SCHEMBL19930458 | 0.84 | SLC6A7 (0.54) | — | |
| SCHEMBL18126696 | 0.83 | CTSS (0.55) | CA12CA1CA2CA7CA9 | |
| SCHEMBL19930445 | 0.78 | ALDH1A1 (0.65) | CA12CA1CA2CA7CA9 | |
| SCHEMBL19930449 | 0.77 | DPP4 (0.49) | — | |
| SCHEMBL14493373 | 0.76 | CA12 (0.87) | CA12CA1CA2CA7CA9 | |
| SCHEMBL19930446 | 0.74 | HSD17B10 (0.63) | CA12CA1CA2CA7CA9 | |
| SCHEMBL19930457 | 0.72 | HSD17B10 (0.62) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180064711-A1 | METHODS FOR TREATING CRYPTOSPORIDIOSIS USING TRIAZOLOPYRIDAZINES | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180064711-A1 | METHODS FOR TREATING CRYPTOSPORIDIOSIS USING TRIAZOLOPYRIDAZINES | CLPP, SI, SAMHD1 | CA12 1536/4885CA1 491/4885CA2 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.